| Sign In to gain access to subscriptions and/or personal tools. |
Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis ratDepartment of Microbiological and Gynaecological Sciences, University of Catania, Catania, Italy
Department of Microbiological and Gynaecological Sciences, University of Catania, Catania, Italy
Institute of Histology and Embryology, School of Medicine, Second University of Naples, Naples, Italy
Institute of Neurology, University of Catania, Catania, Italy
Institute of Neurology, University of Catania, Catania, Italy
Institute of Neurology, University of Catania, Catania, Italy
Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen, Denmark
Department of Clinical Medicine, Prevention and Biotechnological Health, University of Milan, Bicocca, Italy We have evaluated the effect of the immunosuppressant sodium fusidate (fusidin) on the course of acute monophasic experimental encephalomyelitis (EAE) in male Lewis rats. Prophylactic treatment with fusidin, 80 or 120 mg/kg bd wt., markedly ameliorated the course of the disease in rats immunized with myelin basic proteins in complete Freund's adjuvant, entailing delayed onset of symptoms, lower clinical scores and more rapid recovery than PBS-treated control rats. The fusidin-treated, immunized rats exhibited milder mononuclear cell infiltration of brains and spinal cords than control animals. These data provide further evidence for the anti-inflammatory effect of fusidin and suggest that this drug may be valuable for the treatment of human multiple sclerosis.
Key Words: experimental allergic encephalomyelitis immunotherapy multiple sclerosis sodium fusidate
Multiple Sclerosis, Vol. 7, No. 2,
101-104 (2001) |
|||